The price-to-earnings ratio for AMGEN Inc (NASDAQ: AMGN) is 27.07x, which is above its average ratio. Moreover, the 36-month beta value for AMGN is 0.47. Analysts have varying opinions on the stock, with 10 analysts rating it as a “buy,” 6 as “overweight,” 15 as “hold,” and 2 as “sell.”
The public float for AMGN is 536.51M and currently, short sellers hold a 2.47% of that float. On July 10, 2025, AMGN’s average trading volume was 2.92M shares.
AMGN) stock’s latest price update
AMGEN Inc (NASDAQ: AMGN)’s stock price has plunge by -0.16%relation to previous closing price of $297.0. Nevertheless, the company has seen a 2.07% surge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-07-09 that Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid, offering defensive characteristics, capital preservation, and yield over high-growth potential. The diversified product base and growing biosimilars segment reduce concentration and patent cliff risks, supporting Amgen’s stability as a portfolio anchor. Biosimilars face execution, pricing, and demand risks, but continued strong growth could offset upcoming revenue losses from key patent expirations.
AMGN’s Market Performance
AMGEN Inc (AMGN) has seen a 2.07% rise in stock performance for the week, with a 2.13% gain in the past month and a 2.36% surge in the past quarter. The volatility ratio for the week is 2.46%, and the volatility levels for the past 30 days are at 2.65% for AMGN. The simple moving average for the last 20 days is 2.60% for AMGN stock, with a simple moving average of 1.10% for the last 200 days.
Analysts’ Opinion of AMGN
Many brokerage firms have already submitted their reports for AMGN stocks, with Guggenheim repeating the rating for AMGN by listing it as a “Neutral.” The predicted price for AMGN in the upcoming period, according to Guggenheim is $288 based on the research report published on May 20, 2025 of the current year 2025.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see AMGN reach a price target of $305. The rating they have provided for AMGN stocks is “Neutral” according to the report published on April 22nd, 2025.
BofA Securities gave a rating of “Underperform” to AMGN, setting the target price at $256 in the report published on December 10th of the previous year.
AMGN Trading at 4.77% from the 50-Day Moving Average
After a stumble in the market that brought AMGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.51% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AMGN starting from Khosla Rachna, who sale 1,500 shares at the price of $289.68 back on Jun 05 ’25. After this action, Khosla Rachna now owns 8,162 shares of AMGEN Inc, valued at $434,520 using the latest closing price.
Stock Fundamentals for AMGN
Current profitability levels for the company are sitting at:
- 0.22 for the present operating margin
- 0.63 for the gross margin
The net margin for AMGEN Inc stands at 0.17. The total capital return value is set at 0.11. Equity return is now at value 105.67, with 6.51 for asset returns.
Based on AMGEN Inc (AMGN), the company’s capital structure generated 0.9 points at debt to capital in total, while cash flow to debt ratio is standing at 0.21. The debt to equity ratio resting at 9.24. The interest coverage ratio of the stock is 3.19.
Currently, EBITDA for the company is 13.36 billion with net debt to EBITDA at 3.92. When we switch over and look at the enterprise to sales, we see a ratio of 6.1. The receivables turnover for the company is 4.2for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.17.
Conclusion
To wrap up, the performance of AMGEN Inc (AMGN) has been better in recent times. The stock has received a bearish of “sell” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
